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Abstract
Background: Chronic lead exposure causes hypertension and cardiovascular disease. Our purpose was to evaluate the
effects of acute exposure to lead on arterial pressure and elucidate the early mechanisms involved in the development of
lead-induced hypertension.
Methodology/Principal Findings: Wistar rats were treated with lead acetate (i.v. bolus dose of 320 mg/Kg), and systolic
arterial pressure, diastolic arterial pressure and heart rate were measured during 120 min. An increase in arterial pressure
was found, and potential roles of the renin-angiotensin system, Na+,K+-ATPase and the autonomic reflexes in this change in
the increase of arterial pressure found were evaluated. In anesthetized rats, lead exposure: 1) produced blood lead levels of
3761.7 mg/dL, which is below the reference blood concentration (60 mg/dL); 2) increased systolic arterial pressure (Ct:
10963 mmHg vs Pb: 12064 mmHg); 3) increased ACE activity (27% compared to Ct) and Na+,K+-ATPase activity (125%
compared to Ct); and 4) did not change the protein expression of the a1-subunit of Na+,K+-ATPase, AT1 and AT2. Pre-
treatment with an AT1 receptor blocker (losartan, 10 mg/Kg) or an ACE inhibitor (enalapril, 5 mg/Kg) blocked the lead-
induced increase of arterial pressure. However, a ganglionic blockade (hexamethonium, 20 mg/Kg) did not prevent lead’s
hypertensive effect.
Conclusion: Acute exposure to lead below the reference blood concentration increases systolic arterial pressure by
increasing angiotensin II levels due to ACE activation. These findings offer further evidence that acute exposure to lead can
trigger early mechanisms of hypertension development and might be an environmental risk factor for cardiovascular
disease.
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Introduction
Lead is a common environmental contaminant that affects all
the organs and systems of the body and causes numerous acute
and chronic illnesses [1,2]. All humans have lead in their body as a
result of exposure to exogenous sources [3]. This exposure occurs
during the manufacture of ammunition, batteries, sheet lead,
solder, ceramic glazes, caulking, bronze plumbing, military
equipment, drinking water and some surgical equipment [3,4].
Experimental and epidemiological studies suggest a close relation-
ship between lead exposure, hypertension and cardiovascular
disease [5,6,7,8,9].
The effects of lead on human health depend on blood levels and
on the duration of the exposure. The Agency for Toxic Substances
and Disease Registry (ATSDR) considered the reference blood
lead concentration level to be 60 mg/dL, and concentrations that
exceed these values require removal from lead exposure [10,11].
Nevertheless, individuals with baseline blood lead levels of
46.8 mg/dL or 67 mg/dL have shown increases in arterial pressure
[12,13].
In vivo and in vitro studies with animals have shown that chronic
lead exposure causes hypertension and cardiovascular disease by
altering the renin-angiotensin system due to elevated ACE activity
[14–16], inhibition of Na+, K+- ATPase [17], induction of
oxidative stress, reduction of nitric oxide bioavailability [1,18–
21] and depletion of antioxidant reserves [22]. Lead might also act
as a calcium substitute in Ca2+-dependent signaling pathways by
interacting with calmodulin, protein kinase C (PKC) and calcium-
dependent potassium channels [23,24] and stimulating vascular
smooth muscle cell proliferation [25]. Certain peripheral and
central nervous system mechanisms such as increased sympathetic
nerve activity, reduced baroreflex sensitivity and reduced para-
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sympathetic tone have also been implicated in chronic lead-
induced hypertension [26,27,28].
The effect of chronic exposure to lead on arterial pressure was
evaluated by several studies. Carmignani et al. [14,27], Sharifi
et al. [15] and Roncal et al. [29] showed that arterial pressure was
significantly increased by chronic exposure to lead. However, few
reports have evaluated effects of acute exposure to this metal on
arterial pressure. Our group found that acute administration of
high lead concentration (100 mM) reduces myocardial contractility
[30] and affects the endothelium, releasing cyclooxygenase-
derived vasoconstrictors and involving reactive oxygen species
[31]. However, rats acutely exposed to lead below the reference
blood concentration showed an increase in left ventricular systolic
pressure [32].
The current study aimed to explore the effects of acute lead
exposure on arterial pressure and to elucidate the mechanisms
involved in the very early development of lead-induced hyperten-
sion in rats. We accordingly developed an experimental model of
acute lead exposure in rats that produces blood lead levels below
the reference blood concentration [10,33]. We then analyzed the
effects of this treatment on: 1) the renin-angiotensin system; 2)
Na+, K+- ATPase activity; and 3) the participation of the
autonomic reflexes in the increased arterial pressure that occurs
in response to lead exposure. Our findings provide the first
evidence that acute exposure to lead causes an increase in arterial
pressure that is due to increased renin-angiotensin system activity.
Materials and Methods
Animals
The studies were performed on 64 male Wistar rats (280–
330 g). All experiments were conducted in compliance with the
guidelines for biomedical research as stated by the Brazilian
Societies of Experimental Biology (Protocols numbers 003/2007).
The rats were housed at constant room temperature, humidity,
and light cycle (12:12-hr light-dark) with free access to water and
were fed rat chow ad libitum.
The protocols were performed with anesthetized rats due to the
duration of the experiment and the necessity of maintaining stable
arterial pressure. To investigate the acute effects of lead on arterial
pressure, a bolus dose of lead (320 mg/kg) was injected
intravenously. Lead levels were measured in blood by dilution
with a polymer (Triton X-100) and samples were measured in
triplicate by atomic absorption spectrometry (AAS5 EA, Carl
Zeiss, Germany) as previously described [34]. The detection limit
of this equipment is 0.5 mg/dL.
Hemodynamic Measurements
The rats were anesthetized with urethane (1.2 mg/kg IP), and the
carotid artery and jugular vein were cannulated with a polyethylene
catheter (PE-50/Clay-Adams) and filled with heparin (50 U/ml) in
saline. The cannulas were connected to pressure transducers (TSD
104A- Biopac) connected to a preamplifier and to an acquisition
system (MP 30 Biopac Systems, Inc; CA) for pressure measure-
ments. The following parameters were analyzed: systolic (SAP) and
diastolic (DAP) arterial pressure and heart rate (HR).
All animals (n = 10) were followed up for 120 min and SAP,
DAP and HR were recorded before (control condition – time 0)
and at 30, 60, 90 and 120 min after lead administration. To
ensure that the effects were not dependent on time, a time control
experiment (n = 5) was performed under the same conditions with
the administration of distilled water. After these protocols, the
heart and plasma were removed and stored at 280uC until being
used for biochemical measurements.
To assess the participation of the renin-angiotensin system in
the blood pressure increase induced by lead exposure, an
angiotensin converting enzyme (ACE) inhibitor (enalapril maleate,
5 mg/kg) and an AT1 receptor antagonist (losartan, 10 mg/Kg)
were used. To assess the possible influence of the autonomic
reflexes on arterial pressure, we also performed a co-treatment
with the ganglionic blocker hexamethonium (20 mg/Kg). The
animals were anesthetized with urethane (1.2 mg/Kg IP), their
carotid artery was cannulated to measure arterial parameters and
their jugular vein was cannulated for drug infusion. After 20 min
of arterial pressure stabilization, enalapril maleate (n = 5), losartan
(n= 7) or hexamethonium (n= 9) was injected intravenously and
after 30 min the following parameters were measured: SAP, DAP
and HR. In the same animal, lead was injected intravenously and
these data were measured after 1 h of exposure. During the
measurement of arterial pressure, the value reached by the systolic
blood pressure after 60 min of exposure was not different from
that at 120 min. Given this, the influence of other drugs on arterial
pressure were investigated only during 60 min of exposure to lead.
Biochemical Measurements
Plasma ACE activity. The effect of lead on plasma
angiotensin converting enzyme (ACE) activity was determined as
previously described [35,36], after 120 min of exposure. Briefly,
triplicate purified plasma samples (3 mL) were incubated with
40 mL of assay buffer containing 5 mM Hip-His-Leu (Hippuryl–
Histidine–Leucine, ACE substrate) (Sigma Chemical) in 0.4 M
sodium borate buffer and 0.9 M NaCl pH 8.3 for 15 min at 37uC.
The reaction was stopped by adding 190 mL of 0.34 N NaOH.
The product, His–Leu, was measured fluorometrically at 365 nm
excitation and 495 nm emission with a fluoro-colorimeter
(Synergy 2, Biotek, U.S.A.) after the addition of 17 mL of o-
phthaldialdehyde (2%) in methanol. To correct for the intrinsic
fluorescence of the plasma, blanks were included by adding Hip-
His-Leu, NaOH and o-phthaldialdehyde. The activity calculations
were based on Michaelis-Menten first-order kinetics. A calibration
curve with ACE substrate was included in each plate (n = 19).
Na+, K+-ATPase activity
To determine if lead exposure for 120 min was capable of
affecting Na+, K+-ATPase activity, the enzymatic material was
extracted as previously described [37]. The heart (n = 10) was
homogenized in a solution containing 20 mM Tris-HCl and
1 mM EDTA, pH 7.0. The homogenized tissue was centrifuged at
8,800 rpm for 20 min and the precipitate was discarded. To the
supernatant, the same volume of the solution was added and it was
centrifuged at 10,000 rpm again for 1 hr. The precipitate was
resuspended in 20 mM Tris-HCl pH 7.2 to a final volume of
400 mL.
Na+,K+-ATPase activity was assayed by measuring Pi liberation
from 3 mM ATP in the presence of 125 mM NaCl, 3 mMMgCl2,
20 mM KCl and 50 mM Tris-HCl (pH 7.5). The enzyme was
preincubated for 5 min at 37uC and the reaction was initiated by
adding ATP (30 mM). Incubation times and protein concentration
were chosen in order to ensure the measurements were made in
the linear part of the reaction. The reaction was stopped by the
addition of 200 mL of 10% trichloroacetic acid. Controls
containing enzyme preparation added after the addition of
trichloroacetic acid were used to correct for non-enzymatic
hydrolysis of the substrate. All samples were in triplicate. The
specific activity was reported as nmol Pi released per min per mg
of protein unless otherwise stated. The specific activity of the
enzyme was determined in the presence and absence of 5 mM
ouabain. Protein concentrations were measured using the
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Bradford method [38] with bovine serum albumin as the standard.
The Na+, K+-ATPase activity is the difference between the activity
with and without ouabain in mmol fluorescein (mg protein)21 h21.
Western blot analysis
After the experiments, the hearts were homogenized and
proteins (80 mg) were separated by 10% SDS-PAGE gels for
AT1, AT2 and the a-1 Na
+, K+-ATPase subunit. The proteins
were transferred to nitrocellulose membranes, which were
incubated with mouse monoclonal antibodies for AT1 (1:500,
Sigma Chemical, CO, St Louis, USA), AT2 (1:500, Sigma
Chemical, CO, St Louis, USA) or Na+, K+- ATPase a-1 (1:500,
Millipore, San Francisco, U.S.A.). After being washed, the
membranes were incubated with anti-mouse (1:5000, Sigma
Chemical, Co, St Louis U.S.A.) immunoglobulin antibody
conjugated to horseradish peroxidase. After being washed
thoroughly, immunocomplexes were detected using an enhanced
horseradish peroxidase/luminal chemiluminescence system (ECL
Plus, Amersham International, Little Chalfont, UK) and film
(Hyperfilm ECL International). Signals on the immunoblot were
quantified with the National Institutes of Health Image V1.56
computer program. The same membrane was used to determine
a-actin expression using a mouse monoclonal antibody for a-actin
(1:5000, Sigma Chemical, CO, St. Louis, USA), and after being
washed, it was incubated with anti-mouse (1:5000, Sigma
Chemical, Co, St Louis U.S.A.). All reagents for western blotting
were purchased from Sigma Chemical Co.
Drugs Used
The following drugs were used: heparin (Roche Q.F.S.A.,
Brazil), urethane, bovine serum albumin, lead acetate, hexame-
thonium hydrochloride, losartan, enalapril maleate and ouabain
(Sigma Chemical Co., USA). All other reagents used were of
analytical grade from Sigma (St Louis, USA) and E. Merck
(Germany).
Data analysis and statistics
All values are expressed as the mean 6 SEM of the number of
animals used in each experiment. The results were analyzed using
the completely randomized Student’s t-test and one-way ANOVA.
When ANOVA showed a significant treatment effect, Tukey’s post
hoc test was used to compare individual means. Differences were
considered statistically significant at p,0.05. The data was
analyzed and the figures were plotted with GraphPad PrismTM
(Version 2.0, GraphPad Software, USA).
Results
Effect of lead exposure on hemodynamic parameters
The effect of acute exposure to lead on hemodynamic
parameters was assessed in anesthetized rats, as shown in
Table 1. Lead caused a significant increase in SAP after 60 min.
However, no significant change in DAP or HR were observed.
The blood lead level 2 h after exposure was 3761.7 mg/dL
(n = 12). Control rats (n = 4) had levels below the detection limit.
Role of the renin angiotensin system in the arterial
pressure increase induced by lead exposure
Previous reports have demonstrated that chronic lead admin-
istration increases arterial pressure and that this is related to renin-
angiotensin system activity [15–16]. We asked whether acute lead
exposure has similar effects on RAS activity in rats. For this,
losartan and enalapril were administered (10 mg/Kg and 5 mg/
kg IV, respectively) 30 min prior to lead exposure. Losartan and
enalapril reduced SAP and DAP (Figure 1.). In addition, SAP and
DAP did not change after lead administration in rats previously
treated with losartan or enalapril. Pressure values in the presence
of lead remained below the control values, showing that lead did
not increase arterial pressure after losartan or enalapril adminis-
tration.
To investigate the possible mechanisms underlying the role of
the RAS in lead-induced hypertension, plasma ACE activity was
measured. ACE activity was higher in lead-treated than in
untreated rats (27% relative to Ct) (Figure 2. C). However, lead
exposure did not change the expression of the AT1 or AT2
receptors (Figure 2. A–B).
Role of the autonomic reflexes in the arterial pressure
increase induced by lead exposure
To determine whether the autonomic reflexes play a role in the
pressure changes after lead treatment, the ganglionic blocker
hexamethonium was used. Hexamethonium reduced the baseline
systolic and diastolic arterial pressure as expected, but these
parameters increased after lead treatment, attaining values similar
to the control condition, as shown in Figure 3.
Effect of lead exposure on Na+, K+-ATPase activity
To evaluate the function of Na+, K+-ATPase, the activity of this
pump was measured and a significant increase was observed in
lead-exposed rats (125% relative to Ct) (Figure 4. A). However, the
protein levels of the a-1 subunit of Na+, K+-ATPase were not
different between the Ct and Pb groups. These results suggest that
acute lead exposure increases the Na+, K+-ATPase pump’s
activity, but it does not alter the level of the a-1 subunit.
Discussion
Lead has been identified as a hazard and a risk factor for
hypertension development and other cardiovascular diseases [39].
The Agency for Toxic Substances and Disease Registry (ATSDR)
considered the reference blood lead concentration level to be
60 mg/dL [10,11]. However, the results presented here demon-
strate that acute administration of lead results in a concentration
(37 mg/dL) below the blood lead reference. This amount of lead is
capable of enhancing systolic arterial pressure without altering
diastolic pressure or heart rate. Our results also suggest that lead
activates ACE and Na+, K+-ATPase activity.
It is well established that rats chronically treated with high-
concentration of lead show increased arterial pressure. Studies by
Carmignani et al. [14] have shown that exposure to 60 ppm of lead
Table 1. Hemodynamic parameters upon acute lead
exposure.
Ct (0 min) 30 min 30 min 30 min 30 min
SAP
(mmHg)
10863 11363 11863* 11863* 12064*
DAP
(mmHg)
6063 6063 6163 6263 6364
HR
(bpm)
334613 348614 370627 369623 365616
SAP- systolic arterial pressure, DAP- diastolic arterial pressure, HR- heart rate, Ct-
Control. The results are expressed as the mean 6 SEM.
*p,0.05 compared with controls (time 0); n = 10.
doi:10.1371/journal.pone.0018730.t001
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in drinking water for 10 months increases systolic and diastolic
arterial pressure. Other reports have demonstrated an increase of
arterial pressure after 2–8 weeks of exposure to lead at 100 ppm
[15]. Roncal et al. [29] showed that exposure to 150 ppm of lead in
drinking water for 4 weeks increases arterial pressure.
In our protocol we expected that the administration of 320 mg/
Kg, should be diluted in a volume correspondent to a 20% of body
weight, approximately 20 ml for 100 g of rat, attaining 160 mg/dL
in the extracellular fluid. However, blood concentration was
37 mg/dL suggesting that lead accumulates fast in other tissues.
In accordance with those findings, we demonstrate that acute
exposure (2 hours) to lead (37 mg/dL), below the reference blood
concentration, also increased SAP. DAP did not change, as also
observed by Roncal et al. [29]. Our results also showed that 2 h of
lead exposure did not alter heart rate (HR). This finding is
consistent with the studies of Carmignani et al. [14,27], who upon
investigating the effects of chronic exposure to this metal
demonstrated increased cardiac inotropism but no changes in
heart rate. Boscolo and Carmignani [26] also showed an increase
in arterial pressure and cardiac inotropism with a higher dose of
lead, but heart rate was not modified. These authors also
demonstrated central sympathetic nervous system hyperactivity,
reduced baroreflex sensitivity and vagal hypotonia in rats treated
chronically with lead. Similarly, Carmignani et al. [27] reported
that lead appears to increase sympathetic nerve activity by central
mechanisms. Our results show that the increase of SAP induced by
lead was not modified by hexamethonium. This finding also
suggests the role of a peripheral effect as an early mechanism in
hypertension development.
The effects of lead exposure on the circulating renin-angiotensin
system in experimental animals appears to vary depending on the
dose and duration of lead exposure [1]. Carmignani et al. [14]
found a significant increase in plasma angiotensin-converting
enzyme (ACE) activity in rats exposed to lead for 10 months. In a
subsequent study of young adult rats exposed to lead for 2–8
weeks, Sharifi et al. [15] found a steady rise in ACE activity in the
plasma, aorta, kidney and heart. To our knowledge, there are no
studies analyzing the participation of the renin-angiotensin system
in a rat model of acute exposure to lead. We found an increase of
plasma ACE activity in rats acutely exposed to lead. To further
investigate the participation of the renin-angiotensin system in the
effect of lead on arterial pressure, we used losartan, an AT1
receptor blocker, and enalapril, an ACE activity blocker. These
drugs reduced the baseline systolic arterial pressure, suggesting a
role of angiotensin II in the acute lead-exposure effects. The
expression of the cardiac AT1 and AT2 receptors was also
monitored to determine whether lead’s effects could result from
changes in these receptors. However, we found that lead was not
capable of modifying the expression of these receptors.
Karai et al. [40] reported a strong positive relationship between
blood lead and erythrocyte Na+, K+-ATPase activity in lead-
exposed workers. Lee et al. [41] showed that the activation of Na+,
K+-ATPase induced a positive inotropic effect. This was
attributable to increased Ca2+ influx through L-type Ca2+
channels and subsequent sarcoplasmatic reticulum Ca2+ release
via activation of the Src/Erk1/2 signaling cascade. Our results
showed an increase of Na+, K+-ATPase activity that was
independent of the increased expression of the alpha-1 subunit
Figure 1. Changes in arterial pressure. Changes in systolic arterial pressure-SAP (A and C) and diastolic arterial pressure-DAP (B and D) before
(Ct) and after Losartan (Los) or Enalapril (Enal) administration and following lead exposure (Los+Pb; Enal+Pb). A and B show the Losartan protocol; C
and D show the Enalapril protocol. *p,0.05 compared with untreated controls. The number of animals used is indicated in parentheses.
doi:10.1371/journal.pone.0018730.g001
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Figure 2. Effects of lead on protein expression and ACE activity. Effects of lead exposure on the protein expression of the (A) AT1 and (B) AT2
receptors and on (C) ACE activity. *p,0.05 compared with untreated controls. The number of animals used is indicated in parentheses.
doi:10.1371/journal.pone.0018730.g002
Figure 3. Changes in arterial pressure. Changes in systolic arterial pressure (SAP) and diastolic arterial pressure (DAP) before (Ct) and after
Hexamethonium (Hexa) administration and following lead exposure (Hexa+Pb). *p,0.05 compared with untreated controls. The number of animals
used is indicated in parentheses.
doi:10.1371/journal.pone.0018730.g003
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of this pump. Brock et al. [42], Muscella et al. [43], and Zhang
and Mayeux [44] demonstrated a sustained increase in Na+, K+-
ATPase activity caused by Angiotensin II. Thus, the increase of
ATPase activity we found in our experimental conditions could be
associated with the activation of RAS also found in this study.
However, as described years ago, NKA activity in the heart also
helps to synchronize contractile activity generating a positive
inotropic effect. This synchronization occurs because the cardiac
myocytes gain a better resting potential. A slight hyperpolarization
occurs resulting in a better fast component generation and
consequently a synchronized contraction [45]. Moreover, as
previously reported [46], in the vessels lead increases NKA
activity, which reduces vascular tone avoiding an increase of DAP.
Based on this we believe that the increased NKA activity in the
vasculature is the reason to counteract a vasoconstrictor action.
Although observing several similarities among our findings and
the findings obtained with chronic treatments it is necessary to
consider one fact. Acute events trigger cellular responses usually in a
different direction. For example, an increased b-adrenergic
stimulation produces, after a time, downregulation of these
receptors. In such case a chronic response is inverted compared
to the acute one. Indeed, we found in cardiac isolated preparations
chronically treated with lead a reduction of the inotropic response to
isoproterenol. This was interpreted by the results from Carmignani
et al. [27] as a consequence of the increased sympathetic tone.
However, we should add that results obtained from acute
administration enable us to know which mechanisms might act as
a trigger for hypertension. Considering that acute responses are
different from those observed with chronic treatments they will
enable a better understanding of the natural history of lead-induced
hypertension and, consequently, its treatment.
In summary, we found that acute exposure to lead induced an
increase in systolic arterial pressure that was associated with
increased angiotensin II levels due to ACE activation. These
findings also indicate that blood lead concentrations lower than
the reference concentration are a risk factor capable of affecting
cardiovascular function. Thus, the results presented here provide
guidance for revising the lead concentrations considered to be safe
and to be toxic.
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